Simultaneous Plasma Determination of CEA, HCG-Beta and Beta-2-Microglobulin in Patients with Nontrophoblastic Tumors

1980 ◽  
Vol 66 (3) ◽  
pp. 305-309 ◽  
Author(s):  
Alvaro Ruibal ◽  
Juan Gultresa
Keyword(s):  
Renal Function ◽  
Tumor Markers ◽  
Normal Renal Function ◽  
The Other ◽  
Test Of Independence ◽  
Beta 2 ◽  
Beta 2 Microglobulin

With the object of studying the possible usefulness of the simultaneous plasma determination of CEA, HCG-beta and beta 2-microglobulin in patients with nontrophoblastic tumors, we measured by radioimmonoassay the concentrations of these substances in 77 patients with normal renal function. In the group without metastases (32 cases), the percentages of positivities were low and similar for the 3 tumor markers. In the group with metastases (45 cases), the χ2 test of independence between each of the 2 markers at a level of 95 % showed a relationship between the results obtained in the determination of HCG-beta and beta 2-microglobulin, as well as an independence between CEA and HCG-beta results and CEA and beta 2-microglobulin results. These data suggest the utility of determining CEA with only 1 of the other 2 antigens in disseminated tumors.

Beta-2 microglobulin (B2M) is an independent prognostic factor for clinical outcomes in patients with CLL treated with frontline fludarabine, cyclophosphamide, and rituximab (FCR) regardless of age, creatinine clearance (CrCl)

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 7034-7034 ◽  
Author(s):  
A. M. Tsimberidou ◽  
C. Tam ◽  
W. Wierda ◽  
S. O' Brien ◽  
S. Lerner ◽  
...  
Keyword(s):  
Renal Function ◽  
Prognostic Factor ◽  
Clinical Outcomes ◽  
The Other ◽  
Adverse Prognostic Factor ◽  
Younger Age ◽  
Beta 2 ◽  
Beta 2 Microglobulin ◽  
Independent Adverse Prognostic Factor

7034 Introduction: High β2M levels are a risk factor in CLL. PCR therapy has been reported to be better tolerated than FCR in older or with decrease renal function pts (Shanafelt, Blood 108:15a). We assessed the association between age, CrCl, PS, β2M and outcomes in pts treated with FCR. Methods: From 7/99 to 1/04, 300 pts received rituximab 375 mg/m2 D1; fludarabine 25 mg/m2/d D2–3; and cyclophosphamide 250 mg/m2/d D2–3. Serum β2M levels were measured by radioimmunoassay. CrCl was calculated (Cockcroft-Gault equation). Results: The median age was 57 yrs (≥70, 14%). Age ≥70 was associated with fewer FCR courses (p<.0001); lower rates of CR (p=.001), overall response (OR; p=.04), survival (OS; p<.0001), and FFS (p=.008); and higher rates of G3–4 thrombopenia (p<.0001) or anemia (p=.002) compared with age<70. The median CrCl was 90 mL/min (CrCl <70, 27%). Pts with CrCl <70 had higher rates of G3–4 thrombopenia (p=.006) or anemia (p=.01) than others. There were no differences between the 2 groups in the other outcomes. PS was 0 in 40%, 1 in 57%, and 2 in 3% of pts. Better PS was associated with higher rates of CR (p=.007) and FFS (p=.02) but did not affect OR or OS. The median β2M level was 3.7 mg/L (β2M ≥ 4, 43%). The rates of CR, survival, and FFS were lower in pts with β2M ≥ 4 compared with others (p<.0001 each). High β2M levels were associated with older age, lower CrCl levels, poorer PS (p<.0001 each), higher rates of G3–4 neutropenia (p=.005), thrombocytopenia (p=.01), and infections (p=.03), and fewer FCR courses (p=.004). The median follow-up was 5 yrs. The rates of CR, 3-yr OS and 3-yr FFS were 72%, 87% and 76%, respectively. Independent factors predicting response were lower β2M (p=.0004) and lower WBC counts (p=.02). Independent factors predicting longer OS were younger age (p=.001), lower β2M (p=.003) and lower WBC (p=.03). Independent factors predicting longer FFS were lower β2M levels (p=.0006), and lower WBC counts (p=.005). Conclusion: Age ≥70 yrs and poor PS, but not CrCl level were associated with poor clinical outcomes. High β2M levels are an independent adverse prognostic factor for CR, OS, and FFS in the context of other prognostic factors. No significant financial relationships to disclose.

Evidence for Dependance of Beta Thromboglobulin Levels on Renal Function

1979 ◽  
Author(s):  
D. Deppermann ◽  
K. Andrassy ◽  
H. Seelig ◽  
E. Ritz ◽  
D. Post
Keyword(s):  
Renal Failure ◽  
Renal Function ◽  
Serum Concentration ◽  
Normal Renal Function ◽  
Impaired Renal Function ◽  
Sensitive Indicator ◽  
Tubular Proteinuria ◽  
Normal Range ◽  
Beta 2 ◽  
Beta 2 Microglobulin

Beta-Thromboglobulin (TG) is a thrombocytic protein which is released into the circulation upon lysis of thrombocytes. Its serum concentration is thought to be a sensitive indicator of thrombocyte consumption. Although a relation of TG platelet consumption could be observed by us in patients with normal renal function, no such relation was found in pat. with renal failure (RF). Therefore we examined whether TG, similar to beta-2-microglobulin (BMG), behaves like a tubular protein. - Patients and methods - 90 pat. with RF were examined. None of the pat. had diseases with known platelet consumption or medication which interferes with platelets. TG and BMG were measured by RIA. - Results - There was a highly significant correlation between TG, serum creat. (r=0,78) and Ccr (r=0,73) and BMG. The normal range (x ±SD) of TG was 33,9± 9,7 ng/ml and values consistantly about 50 ng/ml were observed at Ccr < 50 ml/l,73 m2. TG was found in tubular proteinuria. - Conclusion - TG is a tubular protein the concentration of which rises in patients with renal failure. This finding invalidates the use of TG for detection of thrombosis in patients with impaired renal function.

Determination of beta 2-microglobulin in human urine and serum by latex immunoassay.

1981 ◽  
Vol 27 (6) ◽  
pp. 832-837 ◽  
Author(s):  
A M Bernard ◽  
A Vyskocil ◽  
R R Lauwerys
Keyword(s):  
Human Urine ◽  
Albumin Solution ◽  
Coated Particles ◽  
Analytical Recovery ◽  
Highly Sensitive ◽  
Human Urine And Serum ◽  
Beta 2 ◽  
Beta 2 Microglobulin ◽  
Urine And Serum

Abstract This highly sensitive method for determination of beta 2-microglobulin (beta 2-m) in human urine or serum is based on direct agglutination by beta 2-m of latex particles on which an antibody against beta 2-m is adsorbed. The agglutination is quantified by counting the remaining unagglutinated particles, or by turbidimetry. A novel aspect of this method is the capability to prevent nonspecific agglutination of the antibody-coated particles by diluting them with an albumin solution of well-defined characteristics (pH, freshness, concentration) just before the assay. The assayable concentration range is 1--32 micrograms/L, the detection limit 0.5 micrograms/L. Within-assay CV, based on 10 determinations of beta 2-m in urine and serum at two different dilutions, ranged from 4.6 to 8.7%. Between-assay CV, calculated from 10 determinations of beta 2-m in urine and serum, was 10 and 8.4%, respectively. Analytical recovery of beta 2-m in urine averaged 97% and in serum 104% (n = 10). No component of urine or serum interfered. Coefficients of correlation for beta 2-m in urine or serum as measured by radioimmunoassay and latex immunoassay were 0.97 and 0.93, respectively. Concentrations of beta 2-m in serum and urine from 33 healthy men (ages 20 to 67 years) averaged 1.5 mg/l and 54 micrograms/g of creatine, respectively.

Serum Beta-2-Microglobulin Level and Residual Renal Function in Peritoneal Dialysis

Nephron ◽  
1993 ◽  
Vol 65 (3) ◽  
pp. 469-471 ◽  
Author(s):  
Gianpaolo Amici ◽  
Giovambattista Virga ◽  
Giorgio Da Rin ◽  
Stefano Grandesso ◽  
Alberto Vianello ◽  
...  
Keyword(s):  
Renal Function ◽  
Peritoneal Dialysis ◽  
Residual Renal Function ◽  
Beta 2 ◽  
Beta 2 Microglobulin

scholarly journals MP547CYSTATIN C AND BETA-2 MICROGLOBULIN - VALUABLE BIOMARKERS OF RESIDUAL RENAL FUNCTION IN PERITONEAL DIALYSIS

2017 ◽  
Vol 32 (suppl_3) ◽  
pp. iii629-iii630
Author(s):  
Carla Moreira ◽  
Liliana Cunha ◽  
Maria Carvalho ◽  
José Oliveira ◽  
Olívia Santos ◽  
...  
Keyword(s):  
Renal Function ◽  
Peritoneal Dialysis ◽  
Residual Renal Function ◽  
Beta 2 ◽  
Beta 2 Microglobulin

Optical Estimation of Beta 2 Microglobulin during Hemodiafiltration - Does It Work?

2015 ◽  
Vol 40 (2) ◽  
pp. 113-119 ◽  
Author(s):  
Fredrik Uhlin ◽  
Jana Holmar ◽  
Pia Yngman-Uhlin ◽  
Anders Fernström ◽  
Ivo Fridolin
Keyword(s):  
Correlation Analysis ◽  
Uv Radiation ◽  
Relative Error ◽  
The Other ◽  
Uv Absorbance ◽  
Dialysis Dose ◽  
Spent Dialysate ◽  
Beta 2 ◽  
Beta 2 Microglobulin ◽  
Surrogate Substances

Background: Currently, urea reduction seems to be the most widely used dialysis dose parameter. The aim of this study was to investigate the possibility to monitor beta 2-microglobulin (β2-M) elimination by utilizing the ultraviolet (UV) absorbance of spent dialysate. Methods: Blood and spent dialysate were collected during two week's sessions in 8 patients, one week in hemodialysis (HD) and one in hemodiafiltration (HDF). Correlation analysis between UV-wavelengths and concentrations of solutes in spent dialysate was performed. The reduction ratio (RR) of concentrations in blood, dialysate and UV-absorbance were compared. Results: Differences between HD and HDF were discovered in wavelength correlation maxima for the solutes. Relative error in RR (%) was larger (p < 0.05) for β2-M than for the other solutes. The most reasonable explanation is that β2-M does not absorb UV-radiation; instead, the absorbance of surrogate substances is measured. Conclusion: A high correlation between UV-absorbance and β2-M can be achieved for HDF but not for HD. Still, UV-absorbance could perhaps be used in solely HDF mode for estimation of β2-M removal.

Sign in / Sign up

Export Citation Format

Share Document